You are here
Donald Goff, MD, is interviewed at APA 2014 on new developments in schizophrenia
Whilst there have been disappointments with the withdrawal of two promising glutamatergic agents from development, Dr Goff notes that there have also been encouraging findings. He cites his recently published study on how genes that are involved in the absorption of folate can predict patients treatment response to folate supplementation. He details other innovative and promising approaches such as combining drugs that enhance neuroplasticity with psychosocial interventions, to reduce negative symptoms.
- What have been the developments in the last few years that have changed the landscape of treating schizophrenia?
- Dr Goff's recent study on genes and response to folate supllementation
- Developments in genetics and personalised medicine
- Advances in treating comordity, especially smoking and substance abuse.
- An evaluation of whether marijuana legislation in the US could lead to a greater risk of developing schizophrenia.
- Difficulties in recommending treatments for refractory patients who don't respond to clozapine
- The problem of non-adherence, and Dr Goff's suggested soloutions such as shared decision making and setting shared long term goals.